Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

Also called NCT06548204

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06548204
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06548204. Randomized; triple masking; primary purpose treatment. Start 2025-01-20 (actual); primary completion 2026-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
Acronym
FEND-AMI
Condition
ST-segment Elevation Myocardial Infarction (STEMI)
Intervention (Drug)
Fexofenadine Hydrochloride
Intervention (Other)
Placebo
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct06548204
Content hash
ff3e21c473dbd28e3a4324862ab682c7827148ae44273b39b390bd266100f1f5